Biogen Inc. Common Stock (BIIB) Financials
Key financial figures for Biogen Inc. Common Stock (Q3 2026).
Biogen Q3 2026 revenue rose 10.6% to $2,804.1 million on the first full quarter of Apellis products, while GAAP diluted EPS swung to a $0.14 loss and non-GAAP EPS fell to $2.62 after $284 million of acquired IPR&D charges. Total revenue was $2,804.1 million versus $2,534.7 million a year earlier (+10.6% reported, +10.2% at constant currency). Specialized immunology revenue (SYFOVRE $191.3 million, EMPAVELI $51.5 million, acquired with Apellis in May 2026) contributed $242.8 million against none in Q3 2025. Excluding it, total revenue was about $2,561 million, roughly +1% (calculated). Growth Portfolio revenue was $1.26 billion, up 49%, and 63% of Core Pharmaceutical revenue. On the outlook: Full year 2026 non-GAAP diluted EPS guidance raised at the low end to $12.20 to $13.00 from $12.00 to $13.00 (reported basis). Underlying guidance of $15.95 to $16.75, less about $3.20 for acquired IPR&D, upfront and milestone charges and about $0.55 of Apellis dilution. Full year total revenue still expected to increase by a mid-single digit percentage versus 2025; combined non-GAAP R&D and SG&A expense expected at approximately $4.95 billion. Figures are for Q3 2026, as Biogen Inc. reported them.
- Revenue
- $2.8B
- Net Income
- -$21M
- EPS
- $-0.14
- Total Assets
- $32.1B
- Operating Cash Flow
- $641M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $2.8B | -$21M | -$0.14 | $600M | |
| Q2 FY2026 | $2.7B | $98M | $0.66 | ||
| Q1 FY2026 | $2.5B | $320M | $2.15 | ||
| Q4 FY2025 | $2.3B | -$48M | -$0.33 | ||
| Q3 FY2025 | $2.5B | $467M | $3.17 | $1.2B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $9.8B | $1.3B | $8.79 | $2.1B | |
| FY2024 | $9.7B | $1.6B | $11.18 | $2.5B | |
| FY2023 | $9.8B | $1.2B | $7.97 | 21.32% | $1.2B |
Frequently asked questions
What was Biogen Inc.'s revenue last quarter?
Biogen Inc. reported revenue of $2.80 billion for Q3 FY2026, up 14.2% from the same period a year earlier.
Is Biogen Inc. profitable?
Not in its most recent reported period. Biogen Inc. reported a net loss of $20.6 million for Q3 FY2026, a net margin of -0.73% on revenue.
How much free cash flow did Biogen Inc. generate?
Biogen Inc. generated free cash flow of $600.4 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Biogen Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.